Evidence map›Paper›PMID 35484611›Full record

ArticleActa neuropathologica communications2022

Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutations.

Michael G Argenziano, Julia L Furnari, Michael L Miller, Yu Sun, Matei A Banu, Justin A Neira, Matija Snuderl, Jeffrey N Bruce, Mary Welch, Paul McCormick and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. H3 K27M mutation in rosette-forming glioneuronal tumors: a potential diagnostic pitfall.Virchows Archiv : an international journal of pathology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Michael G ArgenzianoDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Julia L FurnariDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Michael L MillerDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 1130 St. Nicholas Avenue, New York, NY, 10032, USA.
Yu SunDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 1130 St. Nicholas Avenue, New York, NY, 10032, USA.
Matei A BanuDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Justin A NeiraDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Matija SnuderlDepartment of Pathology, NYU Grossman School of Medicine, New York, USA.
Jeffrey N BruceDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Mary WelchDepartment of Neurology, Columbia University Irving Medical Center, New York, USA.
Paul McCormickDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, USA.
Peter CanollDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 1130 St. Nicholas Avenue, New York, NY, 10032, USA. pc561@cumc.columbia.edu.
Columbia University Irving Medical Center · USColumbia University · USNew York University · US

Funding

Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment RecurrenceR01NS103473 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JEFFREY N BRUCE, Peter Canoll · 2017 to 2026
$4.3M
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMAR01CA161404 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRUCE, JEFFREY N · 2012 to 2017
$2.9M
CAPRI: Columbia Cancer Training Program for Resident-InvestigatorsR38CA231577 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREW, KATHERINE D, SCHWARTZ, GARY K · 2018 to 2021
$1.4M
NCI NIH HHS R01 CA161404NCI NIH HHS R38 CA231577NINDS NIH HHS R01 NS103473
6 · The paper itself

Abstract

We present the case of a 41-year-old man who developed worsening mid-thoracic back pain and imaging revealed a well-circumscribed intramedullary tumor in the thoracic spinal cord. Subtotal resection was performed, and histopathological analysis showed a cytologically bland, minimally proliferative glial neoplasm. Sequencing revealed H3 K27M and an activating PTPN11 mutation. Serial imaging revealed slow tumor regrowth over a three year period which prompted a second resection. The recurrent tumor displayed a similar low grade-appearing histology and harbored the same H3 K27M and PTPN11 mutations as the primary. While the prognostic importance of isolated H3 K27M in spinal gliomas is well-known, the combination of these two mutations in spinal low grade glioma has not been previously reported. Importantly, PTPN11 is a component of the MAPK signaling pathway. Thus, as building evidence shows that low grade-appearing gliomas harboring H3 K27M mutations along with BRAF or FGFR1 mutations have a relatively more favorable course compared to isolated H3 K27M-mutant midline gliomas, the present case provides new evidence for the prognostic importance of activating mutations in other components of the MAPK signaling pathway. This case further highlights the importance of clinico-radio-pathologic correlation when incorporating evolving genetic data into the integrated diagnosis of rare neuroepithelial tumors.

Indexed as

Brain NeoplasmsGliomaAdultHistonesHumansMaleMutationNeoplasm Recurrence, LocalProtein Tyrosine Phosphatase, Non-Receptor Type 11HistonesProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanH3 K27MIntramedullary tumorLow grade gliomaMAPK signaling pathwayPTPN11

Identifiers

PMID35484611
PMCPMC9052613
OpenAlexW4225133848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.